Angeliq (Drospirenone/Estradiol) Patent Expiration, LOE Window & CMS Spending

Angeliq (Drospirenone/Estradiol) by Bayer: FDA Orange Book LOE 2031-10-22, 1 AB generics, $681K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBayer
FDA Application & PathwayN021355 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2031-10-22
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$681K
2024 Medicare Part D Spend$404K
2024 Medicaid Spend$277K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.